Please Wait.....
Report
Global Rituximab Biosimilars Market Report and Forecast 2023-2031
Market Report I 2023-04-06 I 147 Pages I EMR Inc.
Global Rituximab Biosimilars Market Report and Forecast 2023-2031
Global Rituximab Biosimilars Market Outlook
The global rituximab biosimilars market size was valued at USD 2.05 billion in 2022 and is projected to grow at a CAGR of 15.7% during the forecast period of 2023-2031 to reach a value of USD 7.62 billion by 2031. The market growth can be attributed to the increasing prevalence of autoimmune diseases, cancer, and the rising demand for cost-effective alternatives to branded biologics.
Global Rituximab Biosimilars Market: Introduction
Rituximab biosimilars are biologic medications that are highly similar to the reference biologic product, Rituxan (rituximab). They are used to treat various autoimmune diseases and cancers, such as non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. The increasing prevalence of these conditions and the rising demand for cost-effective treatment alternatives to the original biologics are the primary drivers of the market growth. Additionally, the expiration of patents for the reference biologic has paved the way for the development and approval of biosimilars, further fuelling the growth of the rituximab biosimilars market.
Global Rituximab Biosimilars Market- Epidemiology
The prevalence of autoimmune diseases and cancers, for which rituximab is used as a treatment option, has been on the rise. According to the World Health Organization (WHO), non-Hodgkin's lymphoma accounts for around 3% of all cancer cases globally, with an estimated 509,590 new cases and 248,724 deaths in 2021. Chronic lymphocytic leukaemia is the most common type of leukaemia in adults, with an estimated 114,000 new cases in 2021. The incidence of rheumatoid arthritis is also significant, affecting around 1% of the global population. The growing prevalence of these diseases is driving the demand for effective and affordable treatment options, leading to the growth of the rituximab biosimilars market.
Rituximab Biosimilars Market Segmentations
The market can be segmented based on product type, indication, distribution channel, and region:
Market Breakup by Product Type
- Blitzima
- Rixathon
- Others
Market Breakup by Indication Type
- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukaemia
- Rheumatoid Arthritis
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Rituximab Biosimilars Market Scenario
The market has experienced significant growth in recent years, driven by factors such as the increasing prevalence of autoimmune diseases and cancers, patent expirations of the reference biologic, and the rising demand for cost-effective treatment alternatives. North America is currently the largest market for rituximab biosimilars, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of diseases, well-established healthcare infrastructure, and strong investment in research and development.
Europe is also a significant market for rituximab biosimilars, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large patient base, increasing awareness of biosimilars, and government initiatives to promote the adoption of cost-effective treatment options. In addition, the region has a well-established healthcare system, which supports the delivery of rituximab biosimilars. Asia Pacific is another region experiencing significant growth in the rituximab biosimilars market. The region's market growth is driven by factors such as a large population base, increasing prevalence of diseases, and the growing adoption of biosimilars. In addition, government initiatives to improve healthcare access and affordability are helping to drive the growth of the market in the region.
Key Players in the Global Rituximab Biosimilars Market
The report provides a detailed analysis of the key players involved in the rituximab biosimilars market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
- Innovent Biologics Inc
- Gedeon Richter Plc.
- BioXpress Therapeutics SA
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Sandoz International GmbH (Novartis)
- Zydus Lifesciences Ltd.
- Hetero Drugs Limited
- Dr Reddy's Laboratories Ltd
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Zenotech Laboratories
- Napp Pharmaceuticals Limited
- Mundipharma International Limited
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Rituximab Biosimilars Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Rituximab Biosimilars Market
6.1 Global Rituximab Biosimilars Market Overview
6.2 Global Rituximab Biosimilars Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Rituximab Biosimilars Market Historical Value (2016-2022)
6.2.1.2 Global Rituximab Biosimilars Market Forecast Value (2023-2031)
6.3 Global Rituximab Biosimilars Market by Product Type
6.3.1 Market Overview
6.3.1.1 Blitzima
6.3.1.2 Rixathon
6.3.1.3 Others
6.4 Global Rituximab Biosimilars Market by Indication Type
6.4.1 Market Overview
6.4.1.1 Non-Hodgkin's Lymphoma
6.4.1.2 Chronic Lymphocytic Leukemia
6.4.1.3 Rheumatoid Arthritis
6.4.1.4 Others
6.5 Global Rituximab Biosimilars Market by Distribution Channels
6.5.1 Market Overview
6.5.1.1 Hospital-Based Pharmacies
6.5.1.2 Online Pharmacies
6.5.1.3 Retail Pharmacies
6.6 Global Rituximab Biosimilars Market by Region
6.6.1 Market Overview
6.6.1.1 North America
6.6.1.2 Europe
6.6.1.3 Asia Pacific
6.6.1.4 Latin America
6.6.1.5 Middle East and Africa
7 North America Rituximab Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3 Canada
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
8 Europe Rituximab Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 Germany
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 France
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
8.5 Italy
8.5.1 Historical Trend (2016-2022)
8.5.2 Forecast Trend (2023-2031)
8.6 Others
9 Asia Pacific Rituximab Biosimilars Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Japan
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 India
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 ASEAN
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
9.6 Australia
9.6.1 Historical Trend (2016-2022)
9.6.2 Forecast Trend (2023-2031)
9.7 Others
10 Latin America Rituximab Biosimilars Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Argentina
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 Mexico
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Others
11 Middle East and Africa Rituximab Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 United Arab Emirates
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 Nigeria
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 South Africa
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Others
12 Global Rituximab Biosimilars Market Dynamics
12.1 Market Drivers and Constraints
12.2 Drug Adoption Parameters
12.3 SWOT Analysis
12.4 Porter Five Forces Model
12.5 Key Demand Indicators
12.6 Key Price Indicators
12.7 Industry Events, Initiatives, and Trends
12.8 Value Chain Analysis
13 Supplier Landscape
13.1 Innovent Biologics Inc
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Gedeon Richter Plc.
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 BioXpress Therapeutics SA
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Takeda Pharmaceutical Company Limited
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Sandoz International GmbH (Novartis)
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Zydus Lifesciences Ltd.
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Hetero Drugs Limited
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Dr Reddy's Laboratories Ltd
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Zenotech Laboratories
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Napp Pharmaceuticals Limited
13.12.1 Company Overview
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Mundipharma International Limited
13.13.1 Company Overview
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
14 Pricing Models and Strategies (Additional Insight)
14.1 Cost Model
14.1.1 Manufacturing Cost Analysis
14.1.2 Procurement Cost Analysis
14.2 Pricing Strategies
14.2.1 Competitor Pricing Analysis
14.2.2 Key Assessment of Product Attributes
14.2.3 Pricing Benchmark
15 Global Rituximab Biosimilars Market- Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security